StudentShare
Contact Us
Sign In / Sign Up for FREE
Search
Go to advanced search...

Tailoring Tyrosine Kinase Inhibitors to Fit the Lung Cancer Genome - Article Example

Cite this document
Summary
Tailoring Tyrosine Kinase Inhibitors to Fit the Lung Cancer Genome Introduction This paper attempts an in-depth summary of the article “Tailoring Tyrosine Kinase Inhibitors to Fit the Lung Cancer Genome” submitted by Looyenga et al in Translational Oncology,(2011), which provides in detail the implications of tyrosine kinase inhibitors (TKIs) in the treatment of non-small cell lung carcinoma (NSCLC)…
Download full paper File format: .doc, available for editing
GRAB THE BEST PAPER98.3% of users find it useful
Tailoring Tyrosine Kinase Inhibitors to Fit the Lung Cancer Genome
Read Text Preview

Extract of sample "Tailoring Tyrosine Kinase Inhibitors to Fit the Lung Cancer Genome"

Download file to see previous pages

Even earlier to the advent of genome sequencing, traditional biological approaches had shown genetic alterations were a characteristic of NSCLC, making personalised treatment favored in the case of NSCLC. A key understanding was that genetic alterations to critical growth factor signalling pathways regulated cell proliferation, survival, and migration. The kinase cascades were responsible to a large extent on signal propagation along these pathways, making inhibition of kinase enzymatic function an important target for chemotherapies in the treatment of NSCLC.

The tyrosine kinase family of signalling enzymes became the focus of this strategy leading to the development of a range of TKIs, with the promise of potential for more novel TKIs. (2) The TKIs approach to the treatment of NSCLC, while evincing success, also demonstrates the problems that arise in the use of targeted therapeutics for the treatment of genetically heterogeneous populations. Targeted therapies in cancer treatment like TKIs in NSLC are based on the assumption that the specific target has been definitely identified and that focusing on this single target or a narrow range of well defined targets is adequate in the treatment of the tumor.

However, the recent advances in genome sequencing studies have indicated that this basis for NSCLC may not be true, since the possibility of a single genetic event in heterogeneous population is only 15% to 20%, with a majority of the patients showing unique combinations of mutations in many of the known oncogenes and tumor suppressors. This definitely points to heterogeneity and mutational redundancy as the primary reasons for resistance to TKIs therapy in NSCLC and the poor response to this treatment approach. (3). With definite identification of the key driver mutations critical to the success of targeted therapies reliable genetic information becomes very important, and in its absence only therapy decisions are restricted to the histology of the disease.

The availability of genetic information changes this dimension, as more reliable and precise treatment decisions can be taken. Assuming that it is possible to correctly segregate NSCLC patients based on genetic information, then the next question that arises is what is the treatment approach fro each class of tumors. Activation of KRAS mutations are the most commonly seen genetic drivers in lung cancer, and targeting of the downstream signalling effecters or the metabolic by products of Ras transformation is the most promising approach in the treatment of Ras-driven tumors.

Activating mutations to a variety of tyrosine kinases are the drivers for the other two classes of NSCLC. These two classes represent between 40% to 80% of all NSCLCs. This shows the possible usefulness of targeted TKI therapy in case the correct target for tumor is identified. Advances in genome sequencing make this correct target identification more of a reality. (4). The quinazoline class of small small-molecule TKIs targeted to EGFR constitute the most studied treatment for NSCLC. Pre-clinical models suggested that this mode of treatment would be effective, but in actual practice the response was

...Download file to see next pages Read More
Cite this document
  • APA
  • MLA
  • CHICAGO
(“Tailoring Tyrosine Kinase Inhibitors to Fit the Lung Cancer Genome Article”, n.d.)
Retrieved from https://studentshare.org/health-sciences-medicine/1425254-tailoring-tyrosine-kinase-inhibitors-to-fit-the
(Tailoring Tyrosine Kinase Inhibitors to Fit the Lung Cancer Genome Article)
https://studentshare.org/health-sciences-medicine/1425254-tailoring-tyrosine-kinase-inhibitors-to-fit-the.
“Tailoring Tyrosine Kinase Inhibitors to Fit the Lung Cancer Genome Article”, n.d. https://studentshare.org/health-sciences-medicine/1425254-tailoring-tyrosine-kinase-inhibitors-to-fit-the.
  • Cited: 0 times

CHECK THESE SAMPLES OF Tailoring Tyrosine Kinase Inhibitors to Fit the Lung Cancer Genome

The Types of Endometrial Cancer

In the United States, endometrial cancer is the first common female malignancy and it is showing the second common female cancer in… Even though the endometrial cancer is accompanied with high risk of death, the molecular mechanisms of endometrial carcinogenesis are poorly clarified yet.... It is developed when the alteration of cells, which are located in the endometrium and the lining of the uterus, is The most common type of endometrial cancer is endometrioid adenocarcinoma....
9 Pages (2250 words) Essay

Analysis of Gleevac Drug

Gazit in 1989 reported low molecular weight tyrosine kinase inhibitors with selective activity towards EGFR.... Gleevec contains imatinib mesylate that is a tyrosine kinase inhibitor.... Secondly, the targeting of singular molecular defects seemed insufficient in the treatment of highly heterogeneous cancer [11].... Tyrosine kinases mediate many of the signaling pathways by which cancer cells promote their proliferation and survival....
11 Pages (2750 words) Essay

Pharmacodynamics and Pharmacokinetics of Imatinib

nbsp;… The first interest goes on how the drug interrupts the activity of the BCR-Abl receptor tyrosine kinase fusion protein.... Studies show that it does so by acting against tyrosine kinase enzyme that necessitated the signaling cascade necessary the development of cancer....
5 Pages (1250 words) Case Study

Pharmacology: Tyrosine Kinase Inhibitor

TKI binds to the catalytic site of tyrosine kinase by the mechanism of competitive ATP (Adenosine Triphosphate)… Tyrosine kinases are the enzymes that catalyze the movement of ɣ phosphate group to the target protein from the ATP molecules.... tyrosine kinase molecules act as the membrane surface protein for the transduction of signals to the cytoplasm.... Binding Activated tyrosine kinase in turn activates the signalling pathways such as protein kinase C pathway, Scaffolding proteins, Ras/Raf mitogen – activated protein kinase pathway, and phosphoinositol 3' – kinase/Akt pathway (Arora and Scholar, 2005)....
5 Pages (1250 words) Assignment

Enzyme Inhibitors in Breast Cancer Therapy

The present discourse “Enzyme Inhibitors in Breast cancer Therapy” addresses modern methods of treating breast cancer, in particular, such surgical techniques as prophylactic removal of ovaries and shutting down of ovaries in case of detection of estrogen-progesterone dependent tumor on early stage.... hellip; cancer cells are characterized as having the ability to be viable under stressful conditions.... Among all of the different types of cancer, breast cancer is the highest cause of death in women between the ages 20 and 59, having been responsible for 32 percent of all new cancer cases in 2003....
19 Pages (4750 words) Coursework

The ADAMs Metalloprotease Family as Targets of Anticancer Therapy

An example is a conversion of a receptor tyrosine kinase (RTK) ectodomain to a soluble protein or production of intracellular fragments with novel signaling mechanisms.... The author of this paper "The ADAMs Metalloprotease Family as Targets of Anticancer Therapy" examines the targeting of ADAMs in coming up with cancer therapies focusing on the modulation of the HER signaling mechanism, the ADAMs crucial roles in diverse biological processes.... hellip; The epidermal growth factors and HER receptors are involved in cancer cell activities....
8 Pages (2000 words) Report

Features of Forensic Science: Tyrosinase Practical

Some authors use the terminology in terms of melanogenesis inhibitors that mainly focuses on decreasing the formation of melanin regardless of any direct interaction between enzyme and inhibitor.... Tyrosinase inhibitors are widely used in cosmetics and dermatological treatments.... Many potential tyrosinase inhibitors are examined in the presence of L- or L- tyrosine.... For this reason, they could be regarded as being tyrosinase inhibitors (AMERICAN PEPTIDE SYMPOSIUM, & BLONDELLE, S, 2006)....
6 Pages (1500 words) Research Proposal

Treatment of Cancer and Its Progress: Solving Cancer Problems

Chemotherapy is a therapy that enhances the survival of a handpicked cluster of patients with non-small cell lung cancer.... The increase in overall survival of patients suffering from head and neck cancer, colon cancer and non-small cell lung cancer through the utilization of targeted therapies symbolizes improvement in the treatment of cancerous cells among patients.... The paper describes cancer that develops when the body cells of a part of an organ grow out of control....
9 Pages (2250 words) Research Paper
sponsored ads
We use cookies to create the best experience for you. Keep on browsing if you are OK with that, or find out how to manage cookies.
Contact Us